Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI WW FrankfurtCPhI WW Frankfurt
Not Confirmed
Not Confirmed
28-30 October, 2025
Coatings TrendsCoatings Trends
Not Confirmed
Not Confirmed
03-05 September, 2025
Not Confirmed
Not Confirmed
04-06 September, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI WW FrankfurtCPhI WW Frankfurt
Industry Trade Show
Not Confirmed
28-30 October, 2025
Coatings TrendsCoatings Trends
Industry Trade Show
Not Confirmed
03-05 September, 2025
Industry Trade Show
Not Confirmed
04-06 September, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/50-years-of-innovation-mikart-s-legacy-and-what-s-next-in-cdmo-excellence
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/fda-approvals-drop-24-in-h1-2025-gsk-s-uti-med-vertex-s-non-opioid-painkiller-lead-pack-of-first-in-class-meds
10 Jul 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250710413570/en/PharmaJet-Enters-into-MOU-Agreement-with-Egyptian-UPA-and-EVA-Pharma-to-provide-Needle-free-Delivery-for-Routine-Immunization-in-Egypt
30 Jun 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/06/30/3107501/0/en/EVA-Pharma-and-Zhejiang-Jinhua-CONBA-Bio-Pharm-Sign-Strategic-Supply-Agreement.html
26 Jun 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/porton-advanced-and-eva-pharma-sign-mou-to-expand-car-t-cell-therapy-access-in-the-middle-east-and-africa-302491979.html
26 Jun 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/06/26/3106181/0/en/EVA-Pharma-and-BioPharma-Town-Qiantang-District-Hangzhou-Sign-a-Strategic-Cooperation-Agreement.html
05 Feb 2025
// BUSINESSWIRE
08 Jan 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/01/08/3006570/13009/en/Catalyst-Pharmaceuticals-Announces-Settlement-of-FIRDAPSE-amifampridine-Patent-Litigation-with-Teva-Pharmaceuticals.html
Details:
Humalog (insulin) is a peptide based drug, works by showing agonistic action for GLP-1R, mainly indicated for the treatment of patients with type 1 and 2 diabetes.
Lead Product(s): Insulin Lispro,Inapplicable
Therapeutic Area: Endocrinology Brand Name: Humalog
Study Phase: Approved FDFProduct Type: Peptide
Sponsor: Eli Lilly
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 17, 2024
Lead Product(s) : Insulin Lispro,Inapplicable
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Eli Lilly
Deal Size : Inapplicable
Deal Type : Inapplicable
Lilly, EVA Pharma Announce Regulatory Approval for Locally Manufactured Insulin
Details : Humalog (insulin) is a peptide based drug, works by showing agonistic action for GLP-1R, mainly indicated for the treatment of patients with type 1 and 2 diabetes.
Product Name : Humalog
Product Type : Peptide
Upfront Cash : Inapplicable
December 17, 2024
Details:
The collaboration aims to expand access to Olumiant (baricitinib), an orally-administered, small-molecule, JAK inhibitor, in low- to middle-income countries.
Lead Product(s): Baricitinib,Inapplicable
Therapeutic Area: Immunology Brand Name: Olumiant
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Eli Lilly
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 09, 2024
Lead Product(s) : Baricitinib,Inapplicable
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Eli Lilly
Deal Size : Undisclosed
Deal Type : Collaboration
Lilly, EVA Pharma Collaborate To Expand Baricitinib Access in Low-Income Nations
Details : The collaboration aims to expand access to Olumiant (baricitinib), an orally-administered, small-molecule, JAK inhibitor, in low- to middle-income countries.
Product Name : Olumiant
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 09, 2024
Details:
Undisclosed
Lead Product(s): Alpha Lipoic Acid,Inapplicable
Therapeutic Area: Nephrology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Other Small Molecule
Recipient: Ain Shams University
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 29, 2024
Lead Product(s) : Alpha Lipoic Acid,Inapplicable
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Recipient : Ain Shams University
Deal Size : Inapplicable
Deal Type : Inapplicable
Alpha Lipoic Acid in Pediatrics on Hemodialysis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 29, 2024
Details:
The agreement aims to make and sell generic lenacapavir, subject to required regulatory approvals, in 120 high-incidence, resource-limited countries for HIV prevention.
Lead Product(s): Lenacapavir,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Sunlenca
Study Phase: Phase IIIProduct Type: Other Small Molecule
Recipient: Gilead Sciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 10, 2024
Lead Product(s) : Lenacapavir,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Recipient : Gilead Sciences
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Gilead Partners with Six Generic Makers to Expand HIV Prevention Access Globally
Details : The agreement aims to make and sell generic lenacapavir, subject to required regulatory approvals, in 120 high-incidence, resource-limited countries for HIV prevention.
Product Name : Sunlenca
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 10, 2024
Details:
Undisclosed
Lead Product(s): Alpha Lipoic Acid,Inapplicable
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Other Small Molecule
Sponsor: MARC-CRO
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 14, 2023
Lead Product(s) : Alpha Lipoic Acid,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : MARC-CRO
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 14, 2023
Details:
Undisclosed
Lead Product(s): Gleptomet,Metformin,Sitagliptin Phosphate
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Undisclosed
Recipient: Genuine Research Center, Egypt
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 05, 2023
Lead Product(s) : Gleptomet,Metformin,Sitagliptin Phosphate
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Recipient : Genuine Research Center, Egypt
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 05, 2023
Details:
Undisclosed
Lead Product(s): Nirmatrelvir,Ritonavir
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Other Small Molecule
Recipient: Genuine Research Center, Egypt
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 08, 2022
Lead Product(s) : Nirmatrelvir,Ritonavir
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Recipient : Genuine Research Center, Egypt
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 08, 2022
Details:
Undisclosed
Lead Product(s): Egyvax Vaccine,Inapplicable
Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Vaccine
Sponsor: Veterinary Serum & Vaccine Research Institute, Egypt | The Supreme Council of University Hospitals, Egypt | Ministry of Higher Education and Scientific Research, Egypt
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 01, 2022
Lead Product(s) : Egyvax Vaccine,Inapplicable
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Veterinary Serum & Vaccine Research Institute, Egypt | The Supreme Council of University Hospitals, Egypt | Ministry of Higher Education and Scientific Research, Egypt
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Immunogenicity Study of EgyVax Vaccine Candidate for Prophylaxis of COVID-19 Infection
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
February 01, 2022
Details:
Undisclosed
Lead Product(s): Metformin,Inapplicable
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Other Small Molecule
Recipient: Alexandria University
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 13, 2021
Lead Product(s) : Metformin,Inapplicable
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Undisclosed
Recipient : Alexandria University
Deal Size : Inapplicable
Deal Type : Inapplicable
Anti-diabetic Drugs and Fatty Liver Management
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 13, 2021
Details:
Undisclosed
Lead Product(s): Revemact,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Undisclosed
Recipient: Genuine Research Center, Egypt
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 22, 2021
Lead Product(s) : Revemact,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Recipient : Genuine Research Center, Egypt
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 22, 2021
Inspections and registrations
ABOUT THIS PAGE